In conclusion, our study suggests that RICTOR/KRAS-altered LUADs offers unique therapeutic vulnerability, optimally engaged through dual mTORC1/2-MEK1/2 targeting, and underscores the importance of genomic-driven stratification to refine optimal therapeutic functional targeting in NSCLC. The gene discussed is RICTOR; the disease is non-small cell lung carcinoma.